Alkynyl indazole derivative and use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9617222
APP PUB NO 20170096400A1
SERIAL NO

15126730

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SENJU PHARMACEUTICAL CO LTDOSAKA-SHI OSAKA 541-0048

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Machida, Mamiko Osaka, JP 5 0
Machida, Shinnosuke Osaka, JP 3 0
Miyabe, Tomoyo Osaka, JP 2 0
Nakajima, Takeshi Osaka, JP 245 2318
Takeda, Norihiko Kobe, JP 19 75

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 11, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00